Kineta

About

Kineta Inc. is a clinical-stage biotechnology company based in Seattle, Washington. The company specializes in developing next-generation immunotherapies aimed at overcoming cancer immune resistance mechanisms, such as immunosuppression and T cell exhaustion. Kineta distinguishes itself by focusing on innate immunity, in contrast to many competitors that primarily target adaptive immunity. The company's pipeline includes KVA12123, a VISTA-blocking monoclonal antibody currently in Phase 1/2 clinical trials for advanced solid tumors, and an Anti-CD27 Agonist monoclonal antibody in preclinical development designed to activate CD27 pathways and combat T cell exhaustion. Kineta collaborates with notable partners like MSD International Business GmbH and Genentech to enhance its drug development efforts. With a small team of five employees, Kineta is traded on the OTC Markets under the ticker KANT.